SVAS Biosana S.p.A (SVS) Fair Value & Analysis
Healthcare · IT · Market cap €49.0M
Fair value as of: Jul 25, 2026
From 14 valuation models · updated 16 days ago
Fair value updated Jul 25, 2026, revised from €28.38 to €24.96 (−12.1%) since Jun 25, 2026. Share price −5.7% over the past month.
A solid business, screening 200% undervalued on our models.
What matters now
- The price is below even our cautious bear case (€17.43). The market is more pessimistic than our downside scenario.
- Solid quality (51/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (€17.43 to €31.41) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 25, 2026.
How to read this chart
55‑month range €6.17 – €13.48 · fair‑value band €17.43 – €31.41 · the €8.32 price screens below the €24.96 fair value. Dashed = 300-day average. As of Jul 25, 2026.
Analysis
SVAS Biosana S.p.A (SVS) currently trades at €8.32, while our model-based Fair Value estimate is €24.96, implying the stock looks roughly 200.0% undervalued today. The Quality Score stands at 51/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, SVAS Biosana S.p.A generated revenue of €142M at a net margin of 4.8%. Revenue grew 10.4% year over year. It earns a return on equity of 10.4%. Net debt stands at €54.4M. Fundamentals as of Jul 25, 2026
Our scenario range runs from €17.43 (bear case) to €31.41 (bull case); at €8.32, the current price sits below that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 21% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at 200%, SVS screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 14 models by family
Widest divergence: Multiples (€28.57) versus Asset-Based (€8.66). Highest evidence: ROIC Compounder (72).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 25, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 48 · Market factors (momentum, volatility) 50
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
SVAS Biosana S.p.A. engages in the production and marketing of medical devices worldwide. The company offers incontinence aids, traditional dressings, and personal care products for use in incontinence devices, dressings, and personal care product applications.
Full company description
SVAS Biosana S.p.A. engages in the production and marketing of medical devices worldwide. The company offers incontinence aids, traditional dressings, and personal care products for use in incontinence devices, dressings, and personal care product applications. It also offers operating packs, medical devices, infusion and aspiration, linen, advanced dressings, and lubricating gels that are used in haemodynamic, heart surgery, anaesthesia, and critical care applications. In addition, the company provides specialist medical devices for use in oncology, intensive care, chronic illnesses, and surgeries; and medical devices for use in radiology and diagnostic imaging, orthopaedics, cardiology, heart surgery, and critical care applications. SVAS Biosana S.p.A. was founded in 1972 and is based in Somma Vesuviana, Italy.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SVAS Biosana S.p.A reported revenue of €142M in FY2025 versus €81.1M in FY2021, a compound +14.9%/yr. Reported net income was €6.8M in FY2025, compounding +21.0%/yr from FY2021.
Watch SVS: get an alert when its fair value changes →
Peer Group
Medical Devices · 351 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 25, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare SVAS Biosana S.p.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SVAS Biosana S.p.A (SVS) overvalued or undervalued?
What is the fair value of SVS?
What is the quality score of SVS?
What is the revenue of SVAS Biosana S.p.A (SVS)?
What is the net profit margin of SVS?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track SVAS Biosana S.p.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.